Abbott Laboratories

Address:
100 Abbott Park Road
Abbott Park, Illinois
60064-3500
United States of America

Abbott Laboratories articles

Displaying 1 - 8 of 8

Rx implantable cardiac monitor connects to smartphones

Rx implantable cardiac monitor connects to smartphones
Abbott has secured U.S. FDA clearance for the Confirm Rx Insertable Cardiac Monitor (ICM), the world's first and only smartphone compatible ICM designed to help physicians remotely identify cardiac arrhythmias. With FDA clearance Abbott can now provide U.S. patients a new way to monitor for abnormal heart rhythms while staying connected to their physician remotely and being able to engage in their health care.
1st November 2017

Drug-eluting coronary stent released in Europe

Drug-eluting coronary stent released in Europe
Abbott has announced it received CE Mark for XIENCE Sierra, the newest generation of the company's gold-standard XIENCE everolimus-eluting coronary stent system. CE Mark allows sale of the device in the European Union and other countries that recognise CE Mark. Advances in this generation of XIENCE — which is known for its exceptional safety — include new features that make it easier for cardiologists to successfully complete complex procedures that now account for up to 70% of cases.
31st October 2017

DRG system helps patients battling complex regional pain syndrome

DRG system helps patients battling complex regional pain syndrome
Abbott has announced the U.S. launch of the company's Proclaim DRG Neurostimulator System, a new device designed to deliver stimulation to the dorsal root ganglion (DRG) and alleviate pain in patients suffering from complex regional pain syndrome (CRPS) of the lower limbs. With the Proclaim DRG system, Abbott has added new, patient-centric benefits to a device capable of delivering the company's sustained and superior pain relief for patients battling CRPS.
17th October 2017


Glucose monitoring system receives FDA Approval

Glucose monitoring system receives FDA Approval
The U.S. Food and Drug Administration has approved the FreeStyle Libre Flash Glucose Monitoring System, the first continuous glucose monitoring system that can be used by adult patients to make diabetes treatment decisions without calibration using a blood sample from the fingertip (often referred to as a “fingerstick”). The system reduces the need for fingerstick testing by using a small sensor wire inserted below the skin’s surface that continuously measures and monitors glucose levels.
2nd October 2017

Ellipse ICD receives FDA Approval

Ellipse ICD receives FDA Approval
Abbott has announced FDA approval for magnetic resonance (MR)-conditional labeling for one of Abbott's most widely-used ICD and associated high voltage leads. The approval of MR-conditional labeling for the Ellipse ICD with the Tendril MRI pacing lead and Durata and Optisure high voltage leads adds another patient-centric benefit to the device and will help further improve access for patients suffering from abnormally fast heart rhythms who need an ICD and who may need an MRI scan in the future.
28th September 2017

Pacemaker firmware update addresses vulnerabilities

Pacemaker firmware update addresses vulnerabilities
Abbott has notified physicians of updates to its implantable pacemakers and defibrillators as part of its ongoing commitment to continuously improve patient care. The new device updates include a Battery Performance Alert for our implantable cardioverter defibrillators (ICDs) that provides physicians with earlier warning of the potential for the low risk of premature battery depletion.
1st September 2017

HeartMate 3 LVAD receives FDA Approval

HeartMate 3 LVAD receives FDA Approval
Abbott has announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left Ventricular Assist System (also known as an LVAD). The HeartMate 3 system provides a new option for physicians managing advanced heart failure patients in need of short-term hemodynamic support (bridge-to-transplant or bridge to myocardial recovery).
30th August 2017

Cardiac ablation catheter integrates with 3D mapping system

Cardiac ablation catheter integrates with 3D mapping system
Abbott has announced CE Mark of the TactiCath Contact Force Ablation Catheter, Sensor Enabled, developed to make it easier for physicians to more effectively treat atrial fibrillation (AF), a condition in which the upper chambers of the heart beat too fast. When integrated with Abbott's EnSite Precision cardiac mapping system, physicians are able to utilise dual impedance and magnetic technologies to help more precisely model the heart.
17th May 2017


Sign up to view our publications

Sign up

Sign up to view our downloads

Sign up

CES 2018
9th January 2018
United States of America Las Vegas, Nevada
Developing wearable products: technology and opportunities
17th January 2018
United Kingdom Cocoon Networks, London
Smart Mobility Executive Forum
12th February 2018
Germany Berlin
embedded world 2018
27th February 2018
Germany Nuremberg
Industry 4.0 Summit 2018
28th February 2018
United Kingdom Manchester